NVDA

175.51

-0.41%↓

AAPL

252.94

+0.52%↑

MSFT

373.46

-2.49%↓

TSM

341.96

+0.92%↑

AVGO.US

319.16

-0.94%↓

NVDA

175.51

-0.41%↓

AAPL

252.94

+0.52%↑

MSFT

373.46

-2.49%↓

TSM

341.96

+0.92%↑

AVGO.US

319.16

-0.94%↓

NVDA

175.51

-0.41%↓

AAPL

252.94

+0.52%↑

MSFT

373.46

-2.49%↓

TSM

341.96

+0.92%↑

AVGO.US

319.16

-0.94%↓

NVDA

175.51

-0.41%↓

AAPL

252.94

+0.52%↑

MSFT

373.46

-2.49%↓

TSM

341.96

+0.92%↑

AVGO.US

319.16

-0.94%↓

NVDA

175.51

-0.41%↓

AAPL

252.94

+0.52%↑

MSFT

373.46

-2.49%↓

TSM

341.96

+0.92%↑

AVGO.US

319.16

-0.94%↓

Search

Entegris Inc

Open

SectorTechnology

121.6 3.83

Overview

Share price change

24h

Current

Min

114.01

Max

121.94

Key metrics

By Trading Economics

Income

165M

236M

Sales

17M

824M

P/E

Sector Avg

72.026

77.27

EPS

0.7

Dividend yield

0.37

Profit margin

28.596

Employees

7,700

EBITDA

14M

228M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+15.64% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.37%

2.29%

Next Earnings

6 maj 2026

Next Dividend date

20 maj 2026

Next Ex Dividend date

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-1.6B

17B

Previous open

117.77

Previous close

121.6

News Sentiment

By Acuity

50%

50%

163 / 376 Ranking in Technology

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Entegris Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Entegris Inc Forecast

Price Target

By TipRanks

15.64% upside

12 Months Forecast

Average 133 USD  15.64%

High 155 USD

Low 95 USD

Based on 9 Wall Street analysts offering 12 month price targets forEntegris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

70.921 / 78.3859Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

163 / 376 Ranking in Technology

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Entegris Inc

Entegris, Inc. develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions in North America, Taiwan, China, South Korea, Japan, Europe, and Southeast Asia. It operates in three segments: Materials Solutions (MS); Microcontamination Control (MC); and Advanced Materials Handling (AMH). The MC segment solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries; integrated circuit chemical mechanical polishing solutions, high-performance etch and clean chemistries, gases and materials, and safe and materials delivery systems. The MS segment provides materials-based solutions, such as chemical mechanical planarization slurries, pads, deposition materials, process chemistries and gases, formulated cleans, etchants, and other specialty materials. The Advanced Materials Handling segment develops solutions for customers' yields by protecting critical materials during manufacturing, transportation, and storage, which include monitor, protect, transport and deliver critical liquid chemistries, wafers, and other substrates for semiconductor, life sciences and other high-technology industries. The company's customers include logic and memory semiconductor device manufacturers, semiconductor equipment makers, gas and chemical manufacturing companies, and wafer grower companies; and flat panel display equipment makers, panel manufacturers, and manufacturers of hard disk drive components and devices, as well as their related ecosystems. It serves manufacturers and suppliers in the solar and life science industries, electrical discharge machining customers, glass and glass container manufacturers, aerospace manufacturers, and manufacturers of biomedical implantation devices. Entegris, Inc. was founded in 1966 and is headquartered in Billerica, Massachusetts.
help-icon Live chat